Core Viewpoint - Longshen Rongfa (300534.SZ) announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received two approval notices from the National Medical Products Administration for clinical trial supplement applications on July 30, 2025 [1] Group 1 - The clinical trial for the drug Bupropion oral dissolving film has been approved to add specifications of 0.5mg and 1mg [1] - Bupropion oral dissolving film is intended for the treatment of schizophrenia [1] - The supplement application primarily aims to increase the relevant specifications for the clinical trial, which will continue to be conducted [1] Group 2 - According to China's drug registration laws and regulations, after obtaining the clinical trial approval notice, the drug must undergo clinical trials and receive review and approval from the National Medical Products Administration before it can be produced and marketed [1]
陇神戎发(300534.SZ)：控股子公司获得药物临床试验补充申请批准通知书